ANIX vs. VACC, IOBT, CLRB, ORMP, BRNS, CLSD, GNLX, ABEO, PRPH, and PMVP
Should you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Vaccitech (VACC), IO Biotech (IOBT), Cellectar Biosciences (CLRB), Oramed Pharmaceuticals (ORMP), Barinthus Biotherapeutics (BRNS), Clearside Biomedical (CLSD), Genelux (GNLX), Abeona Therapeutics (ABEO), ProPhase Labs (PRPH), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical preparations" industry.
Anixa Biosciences (NASDAQ:ANIX) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk.
Anixa Biosciences has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Anixa Biosciences' return on equity.
Anixa Biosciences currently has a consensus price target of $12.00, suggesting a potential upside of 261.45%. Vaccitech has a consensus price target of $7.63, suggesting a potential upside of 199.02%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Anixa Biosciences is more favorable than Vaccitech.
Anixa Biosciences has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500.
Anixa Biosciences received 1 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
In the previous week, Anixa Biosciences had 1 more articles in the media than Vaccitech. MarketBeat recorded 2 mentions for Anixa Biosciences and 1 mentions for Vaccitech. Vaccitech's average media sentiment score of 0.33 beat Anixa Biosciences' score of -1.23 indicating that Vaccitech is being referred to more favorably in the news media.
29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 22.6% of Anixa Biosciences shares are owned by company insiders. Comparatively, 6.0% of Vaccitech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Vaccitech has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks.
Summary
Anixa Biosciences beats Vaccitech on 10 of the 17 factors compared between the two stocks.
Get Anixa Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anixa Biosciences Competitors List
Related Companies and Tools
